Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BIBW 2992 (Afatinib) Clear all
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Afatinib in Advanced Refractory Urothelial Cancer

NCT02122172
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
Interventions
afatinib dimaleate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Decatur, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Afatinib in Pediatric Tumours

NCT02372006
View directory record Official record
Conditions
Neuroectodermal Tumors, Rhabdomyosarcoma
Interventions
afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 4, 2026, 1:02 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Afatinib 40 MG
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

NCT04497584
View directory record Official record
Conditions
Advanced Squamous Non Small Cell Lung Cancer
Interventions
Afatinib + Prednisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

NCT03157089
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Afatinib, pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 4, 2026, 1:02 AM EDT
Approved For Marketing No phase listed Expanded access

Afatinib Expanded Access Program

NCT01649284
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Goodyear, Arizona • Hot Springs, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

NCT01824823
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
afatinib, placebo
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
272
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 1 Interventional

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

NCT06302621
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Interventions
Afatinib, Pemigatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT02424617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib, Bemcentinib
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Results available

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

NCT02514174
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions
Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
70 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Anaheim, California • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Safety Study of Afatinib for Brain Cancer

NCT02423525
View directory record Official record
Conditions
Brain Cancer
Interventions
Afatinib
Drug
Lead sponsor
Santosh Kesari
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 4, 2026, 1:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
MRTX849, Pembrolizumab, Cetuximab, Afatinib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
221
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

NCT00656136
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
placebo, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

NCT00727506
View directory record Official record
Conditions
Glioma
Interventions
BIBW 2992, TMZ, BIBW 2992 plus TMZ
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 4, 2026, 1:02 AM EDT
Completed No phase listed Observational Results available

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

NCT04750824
View directory record Official record
Conditions
Non-squamous, Non-Small Cell Lung Cancer
Interventions
Afatinib, other systemic therapy
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 3 Interventional Results available

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

NCT01345669
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Placebo, Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
15
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Results available

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

NCT01647711
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dose escalation followed by treatment with MTD
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

NCT01345682
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
Afatinib, Methotrexate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

NCT02451553
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
Interventions
Afatinib Dimaleate, Capecitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

NCT01721525
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Basking Ridge, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

NCT00431067
View directory record Official record
Conditions
Breast Neoplasms
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Encinitas, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions
Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 4, 2026, 1:02 AM EDT